ImmunoCellular Therapeutics Ltd.

ImmunoCellular Therapeutics Ltd. is a Los Angeles-based clinical-stage company that is developing immune-based therapies for the treatment of brain and other cancers. The company has concluded a Phase 2 trial of its lead product candidate, ICT-107, a dendritic cell-based immunotherapy targeting multiple tumor-associated antigens on glioblastoma stem cells. ImmunoCellular's pipeline also includes ICT-121, a dendritic cell immunotherapy targeting the CD133 antigen on stem cells in recurrent glioblastoma; ICT-140, a dendritic cell immunotherapy targeting antigens on ovarian cancer stem cells; and the Stem-to-T-cell research program, which engineers the patient's hematopoietic stem cells to generate antigen-specific cancer-killing T-cells.

Expert Comments:

Jason Kolbert, Maxim Group (9/24/15)
"ImmunoCellular Therapeutics Ltd. today announced it has been awarded $19.9M from the California Institute for Regenerative Medicine to fund the ICT-107 Phase 3 registration trial in patients with newly diagnosed glioblastoma. . .the company stays on track to execute its plan to initiate the Phase 3 ICT-107 trial (n=400) in Q4/15. . .we are excited to see ImmunoCellular continue to develop ICT-107 dendritic cell-based immunotherapy and progress towards its Phase 3 registration trial."

Henry McCusker, Regenerative Medicine Investors (9/24/15)
"ImmunoCellular Therapeutics Ltd. was awarded a $19.9M grant by the California Institute for Regenerative Medicine to fund its ICT-107 Phase 3 registration program in glioblastoma. The company says it is on track to initiate the Phase 3 ICT-107 trial in Q4/15. . .ImmunoCellular has also reached agreement with the FDA on a special protocol assessment relative to the primary and secondary endpoints as well as the statistical plan for the Phase 3 trial."

Jason Kolbert, Maxim Group (8/13/15)
"ImmunoCellular Therapeutics Ltd. has reached agreement with the FDA on a special protocol assessment for the phase 3 registrational trial of ICT-107 to treat patients with newly diagnosed glioblastoma. . .the company will continue to advance the ICT-121 Phase 1 trial with recurrent glioblastoma. . .we reiterate our belief in ICT-107 as a viable therapy for glioblastoma multiforme."

Joseph Pantginis, ROTH Capital Partners (8/13/15)
"ImmunoCellular Therapeutics Ltd. announced the receipt of a special protocol assessment from the FDA for the pending start of the ICT-107 study in front-line glioblastoma. We believe this is a significant achievement for the company, which has been quite engaged with the regulatory authorities following the Phase 2 data showing the survival benefit in HLA-A2 patients. . .we reiterate our Buy rating and $3 target."

Jason McCarthy, Maxim Group (7/2/15)
"In the glioblastoma space is Immunocellular Therapeutics Ltd. whose dendritic cell vaccine, ICT-107, is currently in the planning stages of a pivotal Phase 3 study. The trial could begin in late Q3/15, and interim looks at the data are expected."

"ImmunoCellular Therapeutics Ltd. is a very intriguing name. . .the company has undergone a couple of management changes. . .ImmunoCellular has been very thorough in the types of questions it asked when designing the Phase 2 study of its therapeutic glioblastoma vaccine, ICT-107. . .although the overall primary endpoint data didn't pan out when released in December 2013, the questions that were asked gave the company a pretty clear path forward in showing efficacy for the drug. . .when the data were later analyzed, they showed that the HLA (human leukocyte antigens) status of the patient was going to have a major impact on whether the drug worked or not. . .in patients who were HLA-A2, we saw an encouraging survival benefit with ICT-107 and a path forward. . ." read more >

More Expert Comments

Experts Following This Company

Jerry Isaacson, Managing Director and Senior Analyst – LifeSci Advisors, LifeSci Capital
Jason Kolbert, Senior Analyst – Maxim Group
Henry McCusker – Regenerative Medicine Investors
Joseph Pantginis, Senior Analyst – ROTH Capital Partners

The information provided above is from analysts, newsletters and other contributors. Please contact the company and visit its website before making an investment decision.
Investing Highlights
Pivotal Phase 3 registration trial of lead cancer immunotherapeutic ICT-107 in brain cancer to begin in 2015
Proprietary cancer immunotherapy development pipeline advancing; represents multiple partnering opportunities
Stem-to-T-cell program advancing toward clinical trials; novel immuno-oncology approach
catalyst Calendar
ImmunoCellular Therapeutics Ltd. Content